FREE SAMPLE · DRAFT v1 · not yet published

RNA & In-Vivo Gene-Editing Delivery: Active Clinical Landscape

Who is testing mRNA, self-amplifying RNA (saRNA), circular RNA (circRNA), small interfering RNA (siRNA), antisense oligonucleotides (ASO), CRISPR, base editing, prime editing and in-vivo chimeric antigen receptor (CAR) therapies in humans right now, and what delivery system the registry says they use.

Every trial whose registry entry did not name a delivery system has now been checked against public company, regulator and publication sources: 215 rows were checked by hand, each with a link ("platform-level" where the source covers the company platform rather than the specific product): 179 gained a delivery label and 36 are marked "Not publicly disclosed".

1. Active studies by modality

2. Delivery system (registry text, plus 215 rows checked by hand against public sources)

3. Phase mix

4. Where trials run (top countries by number of studies with a site)

5. Industry programs using an LNP (77)

6. Hand-filled delivery from public sources (215)

Registry did not state the delivery system; filled from the linked company or publication page. "platform-level" means the source describes the company's platform, not this exact product.

7. What the paid edition adds

• A 13-page PDF report: breakdowns by modality, delivery platform, phase, sponsor type, country and therapeutic area, with charts and a top-sponsors table.
• The full spreadsheet (Excel and CSV) of all 397 active trials, with a public source link for every hand-filled delivery label and a data dictionary.
• The change log of registry changes and our label corrections. Tracker Pro adds a monthly refresh and new-trial alerts.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, data processed 2026-10-30. Modifications: active studies only; deduplicated across search terms; modality and delivery labels assigned by keyword rules and may be wrong; 215 rows checked by hand against public company or publication sources (linked per row; 179 labelled, 36 not publicly disclosed); observational studies excluded. Accuracy: in an independent check graded by a second reviewer against registry and company sources (Oct 27, 2026), 78.1% of 64 independently graded trials had both drug type and delivery right (95% interval 66.6-86.5%); 87.5% delivery, 89.1% modality. The errors found have been corrected. This is a single independent sample of 64 trials, not a full audit. Coverage: 17 search terms; 182 of 397 delivery labels come from registry keyword rules and were not hand-checked. Source terms: credited to ClinicalTrials.gov, data date shown, changes described; refreshed regularly. ClinicalTrials.gov is a U.S. Government database; NanoPipeline claims no rights in it. Not investment, medical or legal advice.